Recent Advances in the Pharmacological Management of Atrial Fibrillation

Janelle Y. Gooden, Brian D. Powell, Clement O. Akogyeram, Rowlens Melduni

Research output: Contribution to journalArticle

Abstract

Atrial fibrillation (AF) is a highly prevalent cardiac arrhythmia that leads to hospitalizations for complications and adverse events each year. Despite significant improvement in our therapeutic approaches in the past decade, management of AF remains a difficult task. Novel therapies have failed to terminate AF and prevent its recurrence, and patients with AF continue to have thromboembolic complications. With the increasingly aging population and associated conditions, the prevalence of AF is expected to progressively increase, becoming a public health problem. Most patients with AF have multiple comorbidities and are of advanced age, making long-term anticoagulation challenging. This article provides an overview of the current pharmacological therapies for the management of AF, with particular emphasis on the emerging agents.

Original languageEnglish (US)
Pages (from-to)e118-e138
JournalAmerican Journal of Therapeutics
Volume23
Issue number1
DOIs
StatePublished - Jan 1 2016

Fingerprint

Atrial Fibrillation
Pharmacology
Comorbidity
Cardiac Arrhythmias
Hospitalization
Therapeutics
Public Health
Recurrence
Population

Keywords

  • atrial fibrillation
  • new oral anticoagulants
  • oral factor Xa inhibitors
  • oral thrombin inhibitors
  • stroke prevention

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

Recent Advances in the Pharmacological Management of Atrial Fibrillation. / Gooden, Janelle Y.; Powell, Brian D.; Akogyeram, Clement O.; Melduni, Rowlens.

In: American Journal of Therapeutics, Vol. 23, No. 1, 01.01.2016, p. e118-e138.

Research output: Contribution to journalArticle

Gooden, Janelle Y. ; Powell, Brian D. ; Akogyeram, Clement O. ; Melduni, Rowlens. / Recent Advances in the Pharmacological Management of Atrial Fibrillation. In: American Journal of Therapeutics. 2016 ; Vol. 23, No. 1. pp. e118-e138.
@article{33949d5679ca45aaaee032920b00d1cb,
title = "Recent Advances in the Pharmacological Management of Atrial Fibrillation",
abstract = "Atrial fibrillation (AF) is a highly prevalent cardiac arrhythmia that leads to hospitalizations for complications and adverse events each year. Despite significant improvement in our therapeutic approaches in the past decade, management of AF remains a difficult task. Novel therapies have failed to terminate AF and prevent its recurrence, and patients with AF continue to have thromboembolic complications. With the increasingly aging population and associated conditions, the prevalence of AF is expected to progressively increase, becoming a public health problem. Most patients with AF have multiple comorbidities and are of advanced age, making long-term anticoagulation challenging. This article provides an overview of the current pharmacological therapies for the management of AF, with particular emphasis on the emerging agents.",
keywords = "atrial fibrillation, new oral anticoagulants, oral factor Xa inhibitors, oral thrombin inhibitors, stroke prevention",
author = "Gooden, {Janelle Y.} and Powell, {Brian D.} and Akogyeram, {Clement O.} and Rowlens Melduni",
year = "2016",
month = "1",
day = "1",
doi = "10.1097/MJT.0b013e31828d4532",
language = "English (US)",
volume = "23",
pages = "e118--e138",
journal = "American Journal of Therapeutics",
issn = "1075-2765",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - Recent Advances in the Pharmacological Management of Atrial Fibrillation

AU - Gooden, Janelle Y.

AU - Powell, Brian D.

AU - Akogyeram, Clement O.

AU - Melduni, Rowlens

PY - 2016/1/1

Y1 - 2016/1/1

N2 - Atrial fibrillation (AF) is a highly prevalent cardiac arrhythmia that leads to hospitalizations for complications and adverse events each year. Despite significant improvement in our therapeutic approaches in the past decade, management of AF remains a difficult task. Novel therapies have failed to terminate AF and prevent its recurrence, and patients with AF continue to have thromboembolic complications. With the increasingly aging population and associated conditions, the prevalence of AF is expected to progressively increase, becoming a public health problem. Most patients with AF have multiple comorbidities and are of advanced age, making long-term anticoagulation challenging. This article provides an overview of the current pharmacological therapies for the management of AF, with particular emphasis on the emerging agents.

AB - Atrial fibrillation (AF) is a highly prevalent cardiac arrhythmia that leads to hospitalizations for complications and adverse events each year. Despite significant improvement in our therapeutic approaches in the past decade, management of AF remains a difficult task. Novel therapies have failed to terminate AF and prevent its recurrence, and patients with AF continue to have thromboembolic complications. With the increasingly aging population and associated conditions, the prevalence of AF is expected to progressively increase, becoming a public health problem. Most patients with AF have multiple comorbidities and are of advanced age, making long-term anticoagulation challenging. This article provides an overview of the current pharmacological therapies for the management of AF, with particular emphasis on the emerging agents.

KW - atrial fibrillation

KW - new oral anticoagulants

KW - oral factor Xa inhibitors

KW - oral thrombin inhibitors

KW - stroke prevention

UR - http://www.scopus.com/inward/record.url?scp=84955711632&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84955711632&partnerID=8YFLogxK

U2 - 10.1097/MJT.0b013e31828d4532

DO - 10.1097/MJT.0b013e31828d4532

M3 - Article

VL - 23

SP - e118-e138

JO - American Journal of Therapeutics

JF - American Journal of Therapeutics

SN - 1075-2765

IS - 1

ER -